Moderna, Inc. — MRNA
| Close Price | Market Cap | P/E Ratio | Forward P/E Ratio | Implied Growth* | Implied Forward Growth* | Dividend | P/B Ratio |
|---|---|---|---|---|---|---|---|
| $53.57 | $20.93B | - | -11.6 | N/A | - | - | 2.4 |
Latest Headlines
- · Moderna’s Covid-Flu Vaccine Recommended for Approval in EU
- · European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19
- · Moderna’s combination flu, COVID shot wins over European drug regulators
- · FDA reversal on mRNA-1010 could transform the seasonal influenza vaccines market
- · 3 Reasons to Avoid MRNA and 1 Stock to Buy Instead
- · Moderna's Ups and Downs: Here's What You Need to Know Before Investing.
Revenue & Net Income
| Date | Revenue | Net_Income | EPS | Last_Updated | Revenue_Change | Net_Income_Change | EPS_Change | |
|---|---|---|---|---|---|---|---|---|
| 0 | 2020-12-31 | $274M | $-747M | $-1.96 | 2024-02-03 03:17:10 | N/A | N/A | N/A |
| 1 | 2021-12-31 | $17,736M | $12,202M | $30.31 | 2026-02-27 22:02:17 | 6373.0% | -1733.5% | -1646.4% |
| 2 | 2022-12-31 | $18,875M | $8,362M | $21.26 | 2026-02-27 22:02:17 | 6.4% | -31.5% | -29.9% |
| 3 | 2023-12-31 | $6,754M | $-4,714M | $-12.33 | 2026-02-27 22:02:17 | -64.2% | -156.4% | -158.0% |
| 4 | 2024-12-31 | $3,199M | $-3,561M | $-9.28 | 2026-02-27 22:02:17 | -52.6% | -24.5% | -24.7% |
| 5 | TTM 2025-12-31 | $1,246M | $-1,996M | $-7.26 | 2026-02-17 08:42:53 | -61.1% | -43.9% | -21.8% |
EPS
Forecasts
Y/Y % Change
MRNA Year-over-Year Growth
| 2020 | 2021 | 2022 | 2023 | 2024 | 2026 | 2027 | Average | |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth (%) | 6373.0% | 6.4% | -64.2% | -52.6% | -34.7% | 34.9% | 1043.8% | |
| Revenue Analysts (#) | 0 | 0 | 0 | 0 | 0 | 7 | 7 | |
| EPS Growth (%) | -1733.5% | -31.5% | -156.4% | -24.5% | -26.6% | -35.4% | -334.7% | |
| EPS Analysts (#) | 0 | 0 | 0 | 0 | 0 | 9 | 9 |
Expenses
| Year | Revenue ($) | Cost of Revenue ($) | R&D ($) | SG&A ($) | Facilities / D&A ($) |
|---|---|---|---|---|---|
| 2021 | $17.7B | $2.4B | $2.0B | $567.0M | $232.0M |
| 2022 | $18.9B | $5.1B | $3.3B | $1.1B | $348.0M |
| 2023 | $6.8B | $4.1B | $4.8B | $1.5B | $621.0M |
| 2024 | $3.2B | $1.3B | $4.5B | $1.2B | $189.0M |
| TTM | $1.2B | $268.0M | $2.4B | $710.0M | $148.0M |
| Year | Revenue Change (%) | Cost of Revenue Change (%) | R&D Change (%) | SG&A Change (%) | Facilities / D&A Change (%) |
|---|---|---|---|---|---|
| 2022 | 6.42 | 112.49 | 65.49 | 99.65 | 50.00 |
| 2023 | -64.22 | -19.65 | 47.04 | 36.84 | 78.45 |
| 2024 | -52.64 | -68.69 | -6.23 | -24.21 | -69.57 |
| TTM | -61.05 | -78.98 | -48.12 | -39.52 | -21.69 |
No unmapped expenses.
Balance Sheet
| Metric | Value | |
|---|---|---|
| 0 | Total Assets | $12,135M |
| 1 | Cash | $1,132M |
| 2 | Total Liabilities | $2,805M |
| 3 | Total Debt | $734M |
| 4 | Total Equity | $9,330M |
| 5 | Debt to Equity Ratio | 0.08 |
EPS & Dividend
Valuation
| Share Price | Treasury Yield | Estimates | Fair Value (P/E) | Fair Value (P/S) | Current P/S | Current P/E |
|---|---|---|---|---|---|---|
| $53.57 | 4.0% | Nicks Growth: 8% Nick's Expected Margin: 10% FINVIZ Growth: 26% |
Nicks: 15 Finviz: 73 |
Nick's: 1.486 | 16.8 | - |
| Basis | Year | Nicks Valuation | Nicks vs Share Price | Finviz Valuation | Finviz vs Share Price |
|---|---|---|---|---|---|
| $3.19 Revenue | TTM | $4.74 | -91.2% | $23.25 | -56.6% |
| $5.35 Revenue | 2026 | $7.95 | -85.2% | $39.00 | -27.2% |
| $7.22 Revenue | 2027 | $10.72 | -80.0% | $52.62 | -1.8% |
Implied Growth
No implied growth data available.